Overexpression of FOXM1 predicts poor prognosis and promotes cancer cell proliferation, migration and invasion in epithelial ovarian cancer

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Wen, Ning ^a   Wang, Yu ^a,b   Wen, Li ^a   Zhao, Shu Hua ^b   Ai, Zhen Hua ^b   Wang, Yi ^c   Wu, Bo ^c   Lu, Huai Xiu ^d   Yang, Hong ^b   Liu, Wen Chao ^b   Li, Yu ^c  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^d NAVY GENERAL HOSPITAL   (China)

Author keywords

FOXM1; Invasion; Migration; Ovarian cancer; Prognosis; Proliferation

Indexed keywords

FORKHEAD TRANSCRIPTION FACTOR; FOXM1 PROTEIN, HUMAN; PRIMER DNA;

FEMALE; HUMAN; METABOLISM; METASTASIS; MIDDLE AGED; NEOPLASM; NUCLEOTIDE SEQUENCE; OVARY TUMOR; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR INVASION;

BASE SEQUENCE; DNA PRIMERS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84902654142     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-12-134     Document Type: Article

References (33)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30. 10.3322/caac.21166, 23335087.
2. Tung CS, Wong KK, Mok SC. Biomarker discovery in ovarian cancer. Womens Health 2008, 4:27-40.
3. Coleman RL, Monk BJ, Sood AK, Herzog TJ. Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol 2013, 10:211-224. 10.1038/nrclinonc.2013.5, 3786558, 23381004.
4. Wierstra I, Alves J. FOXM1, a typical proliferation-associated transcription factor. Biol Chem 2007, 388:1257-1274.
5. Laoukili J, Stahl M, Medema RH. FoxM1: at the crossroads of ageing and cancer. Biochim Biophys Acta (BBA)-Rev Cancer 2007, 1775:92-102.
6. Laoukili J, Kooistra MR, Bras A, Kauw J, Kerkhoven RM, Morrison A, Clevers H, Medema RH. FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol 2005, 7:126-136. 10.1038/ncb1217, 15654331.
7. Pilarsky C, Wenzig M, Specht T, Saeger HD, Grützmann R. Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. Neoplasia (New York, NY) 2004, 6:744-750.
8. Liu M, Dai B, Kang SH, Ban K, Huang FJ, Lang FF, Aldape KD, Xie T, Pelloski CE, Xie K. FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. Cancer Res 2006, 3593:3602.
9. Wang Z, Banerjee S, Kong D, Li Y, Sarkar FH. Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer Res 2007, 67:8293-8300. 10.1158/0008-5472.CAN-07-1265, 17804744.
10. Chan D, Yu S, Chiu P, Yao K, Liu V, Cheung A, Ngan H. Over-expression of FOXM1 transcription factor is associated with cervical cancer progression and pathogenesis. J Pathol 2008, 215:245-252. 10.1002/path.2355, 18464245.
11. Bell D, Berchuck A, Birrer M, Chien J, Cramer D, Dao F, Dhir R, Disaia P, Gabra H, Glenn P. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-715. 10.1038/nature10166, 3163504, 21720365.
12. Li Q, Zhang N, Jia Z, Le X, Dai B, Wei D, Huang S, Tan D, Xie K. Critical role and regulation of transcription factor FoxM1 in human gastric cancer angiogenesis and progression. Cancer Res 2009, 69:3501-3509. 10.1158/0008-5472.CAN-08-3045, 19351851.
13. Xia L, Fan D, Wu K. Upregulated FOXM1 Expression Induced by Hepatitis B Virus X Protein Promotes Tumor Metastasis and Indicates Poor Prognosis in Hepatitis B Virus-Related Hepatocellular Carcinoma. Gastroenterology 2012, 57:600-612.
14. Okada K. Overexpression of forkhead Box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer. Ann Surg Oncol 2013, 20:1035-1043. 10.1245/s10434-012-2680-0, 23054116.
15. Xue Y-J, Xiao R-H, Long D-Z, Zou X-F, Wang X-N, Zhang G-X, Yuan Y-H, Wu G-Q, Yang J, Wu Y-T. Overexpression of FoxM1 is associated with tumor progression in patients with clear cell renal cell carcinoma. J Transl Med 2012, 10:200. 10.1186/1479-5876-10-200, 3492118, 23006512.
16. Wang Y, Wen L, Zhao S-H, Ai Z-H, Guo J-Z, Liu W-C. FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients. Lung Cancer 2013, 79:173-179. 10.1016/j.lungcan.2012.10.019, 23177020.
17. Shenhua X, Lijuan Q, Hanzhou N, Xinghao N, Chihong Z, Gu Z, Weifang D, Yongliang G. Establishment of a highly metastatic human ovarian cancer cell line (HO-8910 PM) and its characterization. J exp clin cancer res: CR 1999, 18:233-239.
18. Ochi Y, Atsumi S, Aoyagi T, Umezawa K. Inhibition of tumor cell invasion in the Boyden chamber assay by a mannosidase inhibitor, mannostatin A. Anticancer Res 1992, 13:1421-1424.
19. Xu N, Wu S-D, Wang H, Wang Q, Bai C-X. Involvement of FoxM1 in non-small cell lung cancer recurrence. Asian Pac J Cancer Prev 2012, 13:4739-4743. 10.7314/APJCP.2012.13.9.4739, 23167412.
20. Lok GT, Chan DW, Liu VW, Hui WW, Leung TH, Yao K, Ngan HY. Aberrant activation of ERK/FOXM1 signaling cascade triggers the cell migration/invasion in ovarian cancer cells. PLoS One 2011, 6:e23790. 10.1371/journal.pone.0023790, 3157468, 21858223.
21. Uddin S, Ahmed M, Hussain A, Abubaker J, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Jehan Z. Genome-Wide expression analysis of Middle Eastern colorectal cancer reveals FOXM1 as a novel target for cancer therapy. Am J Pathol 2011, 178:537-547. 10.1016/j.ajpath.2010.10.020, 3070566, 21281787.
22. Lin M, Guo L, Liu H, Du J, Yang J, Zhang L, Zhang B. Nuclear accumulation of glioma-associated oncogene 2 protein and enhanced expression of forkhead-box transcription factor M1 protein in human hepatocellular carcinoma. Histol Histopathol 2010, 25:1269-1275.
23. Xu N, Jia D, Chen W, Wang H, Liu F, Ge H, Zhu X, Song Y, Zhang X, Zhang D. FoxM1 is associated with poor prognosis of non-small cell lung cancer patients through promoting tumor metastasis. PLoS One 2013, 8:e59412. 10.1371/journal.pone.0059412, 3607616, 23536876.
24. Wierstra I. FOXM1 (Forkhead box M1) in Tumorigenesis: Overexpression in Human Cancer, Implication in Tumorigenesis, Oncogenic Functions, Tumor-Suppressive Properties, and Target of Anticancer Therapy. Adv Cancer Res 2012, 119:191-419.
25. Gartel AL. A new target for proteasome inhibitors: FoxM1. Expert Opin Investig Drugs 2010, 19:235-242. 10.1517/13543780903563364, 3532816, 20074015.
26. Hua H, Li M, Luo T, Yin Y, Jiang Y. Matrix metalloproteinases in tumorigenesis: an evolving paradigm. Cell Mol Life Sci 2011, 68:3853-3868. 10.1007/s00018-011-0763-x, 21744247.
27. Vihinen P, Kähäri VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 2002, 99:157-166. 10.1002/ijc.10329, 11979428.
28. Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, Jeltsch M, Mitchell C, Alitalo K, Shima D. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 2003, 161:1163-1177. 10.1083/jcb.200302047, 2172999, 12810700.
29. Hirakawa S, Kodama S, Kunstfeld R, Kajiya K, Brown LF, Detmar M. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med 2005, 201:1089-1099. 10.1084/jem.20041896, 2213132, 15809353.
30. Moghaddam SM, Amini A, Morris DL, Pourgholami MH. Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. Cancer Metastasis Rev 2012, 31:143-162. 10.1007/s10555-011-9337-5, 3350632, 22101807.
31. Schmalfeldt B, Prechtel D, Härting K, Späthe K, Rutke S, Konik E, Fridman R, Berger U, Schmitt M, Kuhn W. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res 2001, 7:2396-2404.
32. Sakata K, Shigemasa K, Nagai N, Ohama K. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary. Int J Oncol 2000, 17:673-754.
33. Ahmad A, Wang Z, Kong D, Ali S, Li Y, Banerjee S, Ali R, Sarkar FH. FoxM1 down-regulation leads to inhibition of proliferation, migration and invasion of breast cancer cells through the modulation of extra-cellular matrix degrading factors. Breast Cancer Res Treat 2010, 122:337-346. 10.1007/s10549-009-0572-1, 19813088.